Relating to direct acting antiviral medications, including prior authorization requirements, and the Iowa medical assistance drug utilization review commission

Where it is now

1. ✓
   Done: IntroducedFebruary 25, 2025
2. ✓
   Done: SubcommitteeMarch 3, 2025
3. ✕
   Stopped: Senate committeeDied when the General Assembly ended
4. Next: Passes the Senate
5. Next: House committeeFunnel: by March 20, 2026
6. Next: Passes the House
7. Next: To the Governor
8. Next: Signed into law

Died when the session ended The 2026 session adjourned on May 3, 2026, the General Assembly’s last regular session. Bills that didn’t pass both chambers died. What’s a funnel?

What’s in it

This bill relates to direct acting antivirals, including prior authorization requirements, and the Iowa medical assistance drug utilization review commission (commission). The bill prohibits the department of health and human services from requiring prior authorization for direct acting antiviral medications used to treat hepatitis C that are on the preferred drug list for the medical assistance program. The bill requires the commission to review, by July 1, 2026, the prescription drug vosevi for placement on the preferred drug list pursuant to U.S.C. §1396r-8 as a preferred direct acting antiviral for treatment of hepatitis C.

From the explanation printed with the bill as introduced, written by the Legislative Services Agency. Amendments adopted later aren’t reflected. Full bill text

Senate subcommittee

Named March 3, 2025. It hasn’t reported yet.

• Sen. Mike Klimesh REmail
• Sen. Mark Costello REmail
• Sen. Zach Wahls DEmail

Three legislators hear a bill first and recommend what the committee should do; it’s the best time to weigh in. How to take part